combining chemotherapy, cd40 agonist, and flt3 ligand in triple-negative breast cancer
Published 2 years ago • 509 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
2:09
triplet combination of chemotherapy, cd40 agonist, and flt3 ligand in triple-negative breast cancer
-
1:29
lig1 deletion predicts chemotherapy resistance in triple-negative breast cancer
-
1:04
are combination approaches the way forward for treating patients with triple-negative breast cancer?
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
1:51
optimal chemotherapy combinations in tnbc gbrca subtypes
-
1:04
future directions in triple-negative breast cancer research
-
1:22
immunological signatures to predict outcomes in patients with tnbc
-
4:40
case 3: the use of combination therapy in triple-negative breast cancer
-
1:01
chemo-immunotherapy for tnbc
-
1:02
combination therapies incorporating adcs in breast cancer
-
1:30
begonia: durvalumab combinations in advanced tnbc
-
1:21
combination therapy io chemo in triple negative breast cancer schmid 2
-
8:01
immune oncology in breast cancer: keynote-086, nci 10013, & aipac
-
1:16
dr. tolaney on platinum-based therapy in neoadjuvant setting of tnbc
-
2:27
monarch: chemo-free options for triple-positive metastatic breast cancer
-
0:50
the addition of platinum compounds to standard chemotherapy for breast cancer patients
-
3:28
immunotherapy in early-stage tnbc - where do we stand?
-
2:59
chemotherapy in combination with immunotherapy for the treatment of metastatic thymic carcinoma
-
2:57
io-io combinations in metastatic tnbc